|Bid||43.68 x 1100|
|Ask||43.84 x 800|
|Day's Range||43.06 - 44.23|
|52 Week Range||40.00 - 45.62|
|Beta (3Y Monthly)||0.40|
|PE Ratio (TTM)||22.53|
|Forward Dividend & Yield||1.74 (3.97%)|
|1y Target Est||N/A|
A newly filed class-action lawsuit accuses international drug maker Sanofi of intentionally concealing risks in its popular heartburn medication, Zantac, which has been found to contain a carcinogenic chemical at 26,000 times the FDA-approved limit, according to the lawsuit filed by Hagens Berman. If you have taken Zantac, you may have ingested carcinogens. The lawsuit, filed Sept. 13, 2019, in the U.S. District Court for the Northern District of California accuses Sanofi and Boehringer Ingelheim of knowingly manufacturing and selling over-the-counter Zantac containing a concealed carcinogen to millions of people in the U.S. suffering from heartburn and other gastrointestinal issues, including sour stomach, acid reflux or gastroesophageal reflux disease (GERD).
PARIS , July 29, 2019 /PRNewswire/ -- Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q2 2019 Change Change at CER H1 2019 Change Change at CER IFRS net sales reported €8,628m +5.5% +3.9% €17,019m +5.9% +4.1% IFRS ...
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it has signed an agreement with Sanofi (SNY) to manufacture Opiant’s investigational agent OPNTOO4 (drinabant) for the treatment of Acute Cannabinoid Overdose (ACO). Opiant intends to reformulate drinabant, a high affinity, selective cannabinoid receptor antagonist, for parenteral administration in an emergency department setting. Opiant licensed exclusive global rights from Sanofi for the development and commercialization of drinabant for the emergency treatment of ACO.
PARIS and TARRYTOWN, N.Y., June 26, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. CRSwNP can be a debilitating condition, with many patients opting for systemic steroids or nasal surgery which often cannot control this disease.
TORONTO , June 11, 2019 /CNW Telbec/ - The 22nd edition of The Sanofi Canada Healthcare Survey uncovered gaps in knowledge that can serve to help guide decision-making among employers who provide health benefit plans to employees. A persistent gap is employers' underestimation of the presence of chronic disease in their workforce, which suggests they may also underestimate the negative impact of unmanaged disease on productivity.
- Pivotal Phase 3 data evaluated isatuximab (anti-CD38) in combination with pomalidomide/dexamethasone in prolonging progression-free survival in relapsed/refractory multiple myeloma - Longer-term Libtayo® ...
BRIDGEWATER, N.J., May 8, 2019 /PRNewswire/ -- For the second consecutive year, Sanofi has been named to DiversityInc's 2019 Top 50 Companies for Diversity. The DiversityInc Top 50 list recognizes the nation's top companies for diversity and inclusion management. Sanofi has also been named to two of DiversityInc's Specialty Lists – Top Companies for LGBT Employees and Top Companies for Philanthropy.
GUILDFORD, England , May 8, 2019 /PRNewswire/ -- FOR UK MEDIA ONLY The first biologic licensed in the EU for severe asthma with type 2 inflammation, as characterised by raised blood eosinophils and/or ...
BRIDGEWATER, N.J., May 1, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Dengvaxia® (Dengue Tetravalent Vaccine, Live) for the prevention of dengue disease caused by serotypes 1 – 4 of the virus in individuals 9 through 16 years of age living in endemic areas of the U.S. with a laboratory-documented prior infection. Dengvaxia is the first and only vaccine approved for protection against dengue in endemic areas of the U.S. "Dengue is endemic and prone to outbreaks in several U.S. territories, including Puerto Rico, the U.S. Virgin Islands and American Samoa.
PARIS , April 26, 2019 /PRNewswire/ -- Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q1 2019 Change Change at CER IFRS net sales reported €8,391m +6.2% +4.2% IFRS net income reported €1,137m +11.9% - IFRS EPS reported ...
BRIDGEWATER, N.J., April 17, 2019 /PRNewswire/ -- Forbes has named Sanofi one of America's Best Employers. This is the first time Sanofi has appeared on the Forbes list. "It is an amazing accomplishment when employees voice their pride and it leads to recognition," said Clint Wallace, Senior Vice President Human Resources, North America and Global Head of HR, Digital and Analytics.
BRIDGEWATER, N.J., April 17, 2019 /PRNewswire/ -- On World Hemophilia Day April 17th, the global bleeding disorders community unites to raise awareness and understanding of hemophilia and areas of unmet needs for patients. Hemophilia is a rare, genetic bleeding disorder in which the ability of a person's blood to clot is impaired, which can lead to bleeding episodes that can cause pain, irreversible joint damage, and life-threatening hemorrhages. Hemophilia most often occurs in boys, and there is currently no cure.
TORONTO , April 11, 2019 /CNW Telbec/ - Sanofi Genzyme, the Specialty Care Business Unit of sanofi-aventis Canda Inc, announced today that Health Canada has issued a Notice of Compliance with conditions (NOC/c) for LibtayoTM (cemiplimab) for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. The market authorization is conditional pending the results of studies to verify its clinical benefit.
BRIDGEWATER, N.J., April 10, 2019 /PRNewswire/ -- Starting in June, Sanofi will further expand its innovative Insulins Valyou Savings Program so people living with diabetes in the United States can pay $99 to access their Sanofi insulins* with a valid prescription, for up to 10 boxes of pens and/or 10 mL vials per month. "It is unacceptable to Sanofi that some people living with diabetes are struggling to pay for their insulin, so we have moved to act creatively and aggressively to help address affordability and access needs," said Michelle Carnahan, Head of North America Primary Care at Sanofi.
As for each quarter, Sanofi prepared this document to assist in the financial modeling of the Group`s quarterly results. Sanofi`s first-quarter 2019 results will be published on April 26, 2019. Sanofi is dedicated to supporting people through their health challenges.
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 11, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids. "For the first time, adolescents with uncontrolled moderate-to-severe atopic dermatitis have an approved biologic treatment option to help control persistent, often debilitating symptoms such as chronic itch and widespread rash.
Press Release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report PARIS, France - March 8, 2019 ...
March 8, 2019 - The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps (CRSwNP). Patients with severe CRSwNP often experience recurrence despite previous treatment with surgery and/or systemic corticosteroids.
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
BRIDGEWATER, N.J., Feb. 27, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved the expanded use of Soliqua® 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL. Previously approved for use as an add-on to diet and exercise in adults with type 2 diabetes who are uncontrolled on long-acting insulin or lixisenatide, Soliqua 100/33 can now also be prescribed for patients uncontrolled on oral antidiabetic medicines. "Many people living with type 2 diabetes are uncontrolled on diet and exercise alone and could require additional interventions to help lower their blood sugar levels," said Michelle Carnahan, North America Head of Primary Care, Sanofi.
Press Release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) ...
February 12, 2019 - Sanofi has appointed Ameet Nathwani, M.D. as Chief Digital Officer in addition to his current role of Executive Vice President, Chief Medical Officer. As Chief Digital Officer, Dr. Nathwani will be responsible for enhancing Sanofi`s strategy to integrate digital technologies and medical science to ultimately improve patient outcomes.
BRIDGEWATER, N.J. and TARRYTOWN, N.Y., Feb. 11, 2019 /PRNewswire/ -- Praluent® (alirocumab) will be made available at a new reduced U.S. list price of $5,850 annually, a 60% reduction from the original price, for both the 75 mg and 150 mg doses, beginning in early March. The new lower-priced Praluent is expected to result in lower patient out-of-pocket costs and represents another step in the companies' efforts to help improve patient affordability and access. This follows an earlier announcement in March 2018, when Sanofi and Regeneron committed to lower the U.S. net price for payers in return for helping to reduce burdensome access barriers for appropriate patients.
PARIS , Feb. 7, 2019 /PRNewswire/ -- Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q4 2018 Change Change at CER 2018 Change Change at CER IFRS net sales reported €8,997m +3.5% +3.9% €34,463m -1.7% +2.5% IFRS net ...